2024-517139-29-00CompletedPhase 1
Effects of DLX-001 on PD, Safety, Tolerability, and PK in Participants with MDD
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 10 Sept 2024
- Start date
- 6 Nov 2024
- Lead sponsor
- Delix Therapeutics Inc.
- Diseases
- Depression
- EU CT number
- 2024-517139-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharma Bio-Research Group | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.